Log in

Checkpoint Therapeutics Stock Forecast, Price & News

+0.06 (+2.52 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $2.44
50-Day Range
MA: $2.81
52-Week Range
Now: $2.44
Volume324,420 shs
Average Volume614,746 shs
Market Capitalization$146.50 million
P/E RatioN/A
Dividend YieldN/A
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the anti-PD-L1 antibodies anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More
Checkpoint Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CKPT



Sales & Book Value

Annual Sales$1.71 million
Book Value$0.34 per share


Net Income$-24,710,000.00
Net Margins-1,664.75%


Market Cap$146.50 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
+0.06 (+2.52 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

How has Checkpoint Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Checkpoint Therapeutics' stock was trading at $1.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CKPT shares have increased by 83.5% and is now trading at $2.44.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Checkpoint Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Checkpoint Therapeutics

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Checkpoint Therapeutics

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics Inc (NASDAQ:CKPT) announced its earnings results on Wednesday, August, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.09). The business had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.38 million. Checkpoint Therapeutics had a negative net margin of 1,664.75% and a negative return on equity of 155.99%.
View Checkpoint Therapeutics' earnings history

What price target have analysts set for CKPT?

3 Wall Street analysts have issued 12 month price objectives for Checkpoint Therapeutics' stock. Their forecasts range from $8.00 to $20.00. On average, they expect Checkpoint Therapeutics' share price to reach $15.00 in the next year. This suggests a possible upside of 514.8% from the stock's current price.
View analysts' price targets for Checkpoint Therapeutics

Are investors shorting Checkpoint Therapeutics?

Checkpoint Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,220,000 shares, an increase of 25.4% from the August 31st total of 1,770,000 shares. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is presently 1.8 days.
View Checkpoint Therapeutics' Short Interest

Who are some of Checkpoint Therapeutics' key competitors?

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the following people:
  • Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)
  • Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32)

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $2.44.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $146.50 million and generates $1.71 million in revenue each year. The company earns $-24,710,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is www.checkpointtx.com.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.